Final ICER Evidence Report on Tezepelumab for Severe Asthma

A final evidence report for the clinical effectiveness and value of Tezepelumab, a treatment for severe asthma, has been released by the Institute for Clinical and Economic Review (ICER). The report finds that although the evidence isn’t adequate to find advantages over other drugs for severe allergic asthma or steroid-dependent asthma, the drug shows a net health benefit for some patients with severe non-eosiniphilic asthma.

According to Dr. David Rind, ICER’s Chief Medical Officer, “ICER previously reviewed biologic therapies for moderate-to-severe asthma, and none of those available at that time were effective in patients without allergic or eosinophilic asthma. Tezepelumab has a new mechanism of action and does reduce exacerbations even for patients without eosinophilia who really have not had good options for treatment until now. For other asthma patients for whom biologics are available, tezepelumab is not clearly superior to those options, and it may be less effective at getting patients off oral steroids than dupilumab.”

Read more and find a link to the full report by clicking here.

(Source: ICER, December 16^th, 2021)